title: Reflections on glycogen and β-amyloid: why does glycogenolytic β2-adrenoceptor stimulation not rescue memory after β-amyloid?
abstract: Normally noradrenaline release ~30 min after training in the day-old chick is essential for memory consolidation by simultaneously increasing both glycogenolysis, by its stimulation of β2-adrenergic (AR) receptors, and glycogen synthesis, by its stimulation of α2-AR receptors in astrocytes. At the same time noradrenaline stimulation of β3-AR receptors increases glucose uptake solely in astrocytes. Intracerebral injection of small oligomeric β-amyloid protein (Aβ1-42) (Aβ) 45 min before one-trial bead discrimination learning in day-old chicks abolishes consolidation of memory 30 min post-learning. The ensuing memory loss can be rescued by injection of selective β3- and β(2-AR agonists (CL316243 and zinterol), which also have the ability to consolidate weakly-reinforced learning into long-term memory. However, although CL316243 rescues Aβ-induced memory loss over a similar time period to when it consolidates weak learning (up to 25 min post training), zinterol is effective over a more limited time period and unexpectedly it does not rescue at the time it promotes glycogenolysis. Injection of Aβ into the hippocampus and the locus coeruleus (LoC) also produces similar memory deficits and injection of both AR agonists into a cortical area can rescue memory from LoC Aβ. We have previously shown that β3-AR stimulation increases astrocytic glucose uptake and have suggested there may be sensitization or upregulation of the receptor. Since β2-AR stimulation does not rescue memory at the time it promotes glycogenolysis, but the receptor does not appear to be impaired, it is suggested that Aβ may be causing an impairment in the synthesis of readily available glycogen.
authors.affiliation: Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Melbourne, 3052, VIC, Australia, marie.gibbs@monash.edu.
authors.forename: Marie
authors.initials: M
authors.lastname: Gibbs
mesh_terms: D058666:Adrenergic beta-2 Receptor Agonists / Q000494:pharmacology / Q000627:therapeutic use*; D058667:Adrenergic beta-3 Receptor Agonists / Q000494:pharmacology; D000544:Alzheimer Disease / Q000378:metabolism; D016229:Amyloid beta-Peptides / Q000378:metabolism* / Q000633:toxicity; D000818:Animals; D001253:Astrocytes / Q000187:drug effects / Q000378:metabolism; D002645:Chickens; D004149:Dioxoles / Q000494:pharmacology; D004983:Ethanolamines / Q000494:pharmacology; D005947:Glucose / Q000378:metabolism; D006003:Glycogen / Q000096:biosynthesis / Q000378:metabolism*; D038362:Glycogen Synthase Kinase 3 / Q000378:metabolism; D050261:Glycogenolysis; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism; D008125:Locus Coeruleus / Q000187:drug effects / Q000378:metabolism; D008569:Memory Disorders / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D057567:Memory, Long-Term / Q000502:physiology; D008959:Models, Neurological; D010446:Peptide Fragments / Q000633:toxicity*; D018343:Receptors, Adrenergic, beta-2 / Q000502:physiology*; D013997:Time Factors
chemical_list: D058666:Adrenergic beta-2 Receptor Agonists; D058667:Adrenergic beta-3 Receptor Agonists; D016229:Amyloid beta-Peptides; D004149:Dioxoles; D004983:Ethanolamines; D010446:Peptide Fragments; D018343:Receptors, Adrenergic, beta-2; C075222:amyloid beta-protein (1-42); C076126:disodium (R,R)-5-(2-((2-(3-chlorophenyl)-2-hydroxyethyl)-amino)propyl)-1,3-benzodioxole-2,3-dicarboxylate; C002904:zinterol; D006003:Glycogen; D038362:Glycogen Synthase Kinase 3; D005947:Glucose